Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099467 | 0.82 | MAPT (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6701751 | 0.79 | ADORA3 (0.52) | KDM4EALDH1A1SMN1; SMN2RAD52MEN1 | |
| SCHEMBL2761000 | 0.78 | ADORA3 (0.41) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL5528653 | 0.76 | GPR3 (0.48) | ALDH1A1HPGDHSD17B10PDPK1CA12 | |
| SCHEMBL3817794 | 0.76 | PDE4A (0.37) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL487415 | 0.73 | ALDH1A1 (0.44) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7072625 | 0.73 | SMN1; SMN2 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5507881 | 0.73 | SMN1; SMN2 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL9076301 | 0.73 | SMN1; SMN2 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL487627 | 0.73 | MAOA (0.42) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20080213308-A1 | Imidazoquinoline Compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1797091-A2 | IMIDAZOQUINOLINE COMPOUNDS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006031878-A2 | IMIDAZOQUINOLINE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096103-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | KDM4E 2683/4885ALDH1A1 3836/4885GLA 4226/4885 |
| US-20110217323-A1 | IMIDAZOQUINOLINE COMPOUNDS | IFNG, IRF3, MYD88 | KDM4E 2683/4885ALDH1A1 3836/4885GLA 4226/4885 |
| US-20080213308-A1 | Imidazoquinoline Compounds | IFNG, IRF3, MYD88 | KDM4E 2683/4885ALDH1A1 3836/4885GLA 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.